556 Shares in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Acquired by Howe & Rusling Inc.

Howe & Rusling Inc. purchased a new stake in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 556 shares of the company’s stock, valued at approximately $48,000.

A number of other hedge funds have also modified their holdings of PJP. Joseph Group Capital Management raised its position in shares of Invesco Pharmaceuticals ETF by 16.0% during the 3rd quarter. Joseph Group Capital Management now owns 15,080 shares of the company’s stock valued at $1,312,000 after purchasing an additional 2,079 shares during the period. Secure Asset Management LLC purchased a new stake in Invesco Pharmaceuticals ETF in the 3rd quarter worth $229,000. HBW Advisory Services LLC bought a new stake in Invesco Pharmaceuticals ETF during the third quarter valued at about $509,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of Invesco Pharmaceuticals ETF by 49.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 6,826 shares of the company’s stock valued at $561,000 after acquiring an additional 2,266 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of Invesco Pharmaceuticals ETF by 87.7% in the second quarter. Envestnet Asset Management Inc. now owns 23,878 shares of the company’s stock valued at $1,963,000 after acquiring an additional 11,156 shares in the last quarter.

Invesco Pharmaceuticals ETF Trading Up 0.9 %

NYSEARCA:PJP opened at $84.68 on Thursday. The stock has a 50-day moving average price of $86.95 and a 200 day moving average price of $84.56. The stock has a market capitalization of $287.05 million, a P/E ratio of 21.48 and a beta of 0.61. Invesco Pharmaceuticals ETF has a 12-month low of $69.53 and a 12-month high of $89.87.

Invesco Pharmaceuticals ETF Company Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.